Corporate & Investor Presentation

Why invest? - driving long-term shareholder value Market Dynamics Growth & Innovation Financial Results • Underpenetrated markets in sleep and COPD • Healthcare costs continue to increase • Focus on improving patient outcomes • Value-based technology solutions Global leader in digital health for sleep and respiratory care • Long-term growth opportunities •8,100+ patents and designs •~7-8% of revenue invested in R&D • Historical revenue and profit growth . • Recurring revenue • Operating excellence program • Strong track record of disciplined capital deployment Total Shareholder Return (NYSE shares as of 3/31/2021)" 1-yr 32% 3-yr 104% ☐ 5-yr 261% 5 2021 ResMed | Corporate & Investor Presentation - updated 29APR21 ResMed

View entire presentation